Ohana Biosciences Announces Appointment of David Sable, MD, to Board of Directors
CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first semen biology platform, today announced the appointment of David Sable, MD, to its board of administration. World-renowned reproductive endocrinologist, Dr. Sable brings to Ohana over 30 years of medical and reproductive health expertise. Dr Sable is currently leading the healthcare and life sciences investments for special situation life insurance funds.
“David is one of the leading voices in reproductive health and brings a forward-thinking perspective that will bring tremendous value to the Ohana team and our bold mission to transform reproductive health, ”said Amber Salzman, Ph. D., President and Chief Executive Officer. Ohana officer. “Her continued advocacy for significant advancements that can help people on their reproductive journey, from helping those struggling with fertility to innovation that can help people have healthier babies, matches our own commitment to advancing the field through new approaches using semen. biology.”
Dr Sable is an obstetrician-gynecologist and reproductive endocrinologist, and he is widely recognized as an innovator in reproductive health and an early adopter of preimplantation genetic diagnosis (PGD) to help people using IVF detect chromosomal abnormalities in embryos. After graduating from Wharton School and the University of Pennsylvania School of Medicine, Dr Sable trained in Obstetrics and Gynecology at New York Hospital-Cornell Medical Center and Reproductive Endocrinology at Brigham and Women’s Hospital. He co-founded and directed the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was the founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015.
Currently, Dr Sable is an Assistant Professor in the Department of Biology at Columbia University, and has lectured on healthcare investment, biotechnology policy and business development at institutions such as the Wharton. School, New York University, Rockefeller University and Rutgers, among others. others. He is also a director of Oova, MedAnswers, Celmatix and Hamilton Thorne Ltd., member of the scientific advisory board and observer of the board of directors of TMRW Life Sciences, served as a director of the non-profit advocacy organization RESOLVE and former member of the medical and scientific council. advice from Ovascience and Progyny.
“Ohana’s unique understanding of semen biology has generated a pipeline of diverse reproductive health commodity opportunities in the most important areas of the reproductive journey, including contraception, fertility and pregnancy, and human health. child, ”said Dr Sable. “I am excited about the opportunity to work with such an exemplary group of researchers and colleagues who are advancing science in this important, but little-studied, area of human reproduction.
About Ohana Biosciences
At Ohana Biosciences, we are at the forefront of a reproductive health revolution through our premier platform of semen-based technologies. We started with a vision to reinvent global reproductive health and help all people create the healthy families they dream of – when they’re ready. Today, we believe that our unprecedented understanding of semen biology, coupled with our pioneering research, will turn our vision into reality. Through our platform, we focus on the fundamental components of reproductive health: fertility, pregnancy complications, inherited diseases, developmental disorders and non-hormonal contraception. By advancing research on fertility treatments, new technologies to reduce pregnancy complications, disease transmission and developmental disabilities, and enabling non-hormonal contraception, Ohana is committed to becoming a leader in reproductive health and providing life-changing options. Ohana was founded in 2016 by Flagship Pioneering and is based in Cambridge, Mass. For more information, please visit www.OhanaBio.com.